MedMira to Participate in Military Health System Research Symposium
August 13 2012 - 8:30AM
PR Newswire (Canada)
HALIFAX, Aug. 13, 2012 /CNW/ - MedMira Inc., (MedMira) , a
developer of rapid diagnostic technology and solutions, announced
today that it is participating in the Military Health System
Research Symposium (MHSRS) taking place August 13-16, 2012 in Fort
Lauderdale, FL. During the symposium, MedMira will discuss and
demonstrate its unique multiplex rapid diagnostics which are
critical tools in the treatment and care of individuals wounded in
combat. MHSRS is the premier scientific meeting to address the
unique medical needs of the warfighter. The symposium is a
collaborative environment for military medical care providers with
deployment experience, Department of Defense (DoD) scientists,
academia, and industry to facilitate discussions and address the
advancement of research and health care development in areas of
Combat Casualty Care, Military Operational Medicine, Clinical and
Rehabilitative Medicine, and Military Infectious Disease Research
Programs. "This event provides us with an ideal opportunity to
showcase our rapid diagnostics and technology platform and allows
us to continue building key relationships with military healthcare
personnel within the US Army and other military organizations
around the world," said Hermes Chan, CEO, MedMira Inc. "MHSRS
attendees will be keen to see and learn more about our Multiplo
Rapid HBV/HIV/HCV Antibody Test, for which we were recently awarded
a US Army contract to advance, fully commercialize, and obtain US
Food and Drug Administration approval." In July 2012, MedMira was
awarded a U.S. Army Medical Research Acquisition Activity (USAMRAA)
contract valued at USD$4,266,144 to advance and fully commercialize
its multiple rapid test that simultaneously detects three of the
most serious infectious diseases, namely HIV-1/2, Hepatitis B, and
C antibodies within three minutes using just a small drop of blood.
About MedMira MedMira is a leading developer and manufacturer of
flow-through rapid diagnostics and technologies. The Company's
tests provide hospitals, labs, clinics and individuals with
reliable, rapid diagnosis for diseases such as HIV and hepatitis C
in just three minutes. The company's tests are sold under the
Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's
rapid flow-through HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For more
information visit MedMira's website at www.medmira.com. This news
release contains forward-looking statements, including statements
relating to growth in the Company's business, earnings and
profitability, and trends in demand for the Company's products,
which involve risk and uncertainties and reflect the Company's
current expectation regarding future events including statements
regarding possible future growth and new business
opportunities. Actual events could materially differ from
those projected herein and depend on a number of factors including,
but not limited to, changing market conditions, successful and
timely completion of clinical studies, uncertainties related to the
regulatory approval process, establishment of corporate alliances
and other risks detailed from time to time in the company quarterly
filings. Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. MEDMIRA INC. CONTACT: MedMira
Contact:Andrea Young, Corporate CommunicationsTel:
902-450-1588Email: ayoung@medmira.com
Copyright
MedMira (TSXV:MIR)
Historical Stock Chart
From Jun 2024 to Jul 2024
MedMira (TSXV:MIR)
Historical Stock Chart
From Jul 2023 to Jul 2024